Evaluation of a novel biomarker of type XXVIII collagen formation, PRO-C28, in samples from cancer and heart failure with preserved ejection fraction patients
Impact
Scholar |
Other documents of the author: Reese-Petersen, Alexander; Willumsen, Nicholas; Palau, Patricia; Nunez, Julio; Sun, Shu; manon-jensen, tina; Kamall, Bibi; Karsdal, Morten; Genovese, Federica
Metadata
Show full item recordcomunitat-uji-handle:10234/9
comunitat-uji-handle2:10234/36080
comunitat-uji-handle3:10234/36082
comunitat-uji-handle4:
INVESTIGACIONThis resource is restricted
https://doi.org/10.1016/j.jpba.2021.114272 |
Metadata
Title
Evaluation of a novel biomarker of type XXVIII collagen formation, PRO-C28, in samples from cancer and heart failure with preserved ejection fraction patientsAuthor (s)
Date
2021-08-03Publisher
Elsevier; American Association of Pharmaceutical ScientistsISSN
0731-7085; 1873-264XBibliographic citation
Reese-Petersen, A. L., Willumsen, N., Palau, P., Nunez, J., Sun, S., Jensen, T. M., ... & Genovese, F. (2021). Evaluation of a novel biomarker of type XXVIII collagen formation, PRO-C28, in samples from cancer and heart failure with preserved ejection fraction patients. Journal of Pharmaceutical and Biomedical Analysis, 204, 114272.Type
info:eu-repo/semantics/articleVersion
info:eu-repo/semantics/publishedVersionSubject
Abstract
Increased turnover of extracellular matrix proteins is seen in many different diseases and is an underlying and driving feature of pathogenesis. An increased ratio of formation over degradation of extracellular matrix ... [+]
Increased turnover of extracellular matrix proteins is seen in many different diseases and is an underlying and driving feature of pathogenesis. An increased ratio of formation over degradation of extracellular matrix proteins, such as collagens, leads to accumulation of proteins in the tissues, ultimately impairing organ function. Understanding how this balance is regulated is key to providing deeper insight into high extracellular matrix turnover diseases. Type XXVIII collagen is a novel collagen with limited information available in relation to expression, tissue prevalence and clinical implication. We generated a novel, technically robust ELISA to measure a C-terminal fragment of type XXVIII collagen in plasma and serum (PRO-C28). PRO-C28 was found to be significantly elevated in circulation in patients with heart failure with preserved ejection fraction (HFpEF) and in patients with lung cancer. Additionally, PRO-C28 correlated significantly to NT-proBNP levels in HFpEF patients. PRO-C28 levels were elevated in diseases characterized by high ECM-turnover. This suggests that type XXVIII collagen may play a role in fibroproliferative disorders in the heart and the lungs. [-]
Is part of
Journal of Pharmaceutical and Biomedical Analysis 204 (2021) 114272Rights
0731-7085/© 2021 Elsevier B.V. All rights reserved.
http://rightsstatements.org/vocab/InC/1.0/
info:eu-repo/semantics/restrictedAccess
http://rightsstatements.org/vocab/InC/1.0/
info:eu-repo/semantics/restrictedAccess
This item appears in the folowing collection(s)
- MED_Articles [667]